falsefalse

The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma - Episode 4

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

,

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Examining the Role of Liver Function in HCC
    EP. 2: HCC Staging: Improving Treatment Strategies
    EP. 3: Locoregional Therapies for Intermediate-Stage HCC
    Now Viewing
    EP. 4: HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials
    EP. 5: Emerging Therapies in Intermediate-Stage HCC
    EP. 6: Updates from IMbrave150, LEAP-002, and HIMALAYA Trials
    EP. 7: Comorbidity Considerations for HCC Treatment
    EP. 8: The Evolving Landscape of Second-Line Therapies in HCC Management
    EP. 9: Additional Second-Line Treatments for HCC
    EP. 10: Real-World Evidence on Second-Line Therapy Selection and Outcomes
    EP. 11: Pioneering Breakthroughs in HCC Treatment

    Related Content:

    The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular CarcinomaUCLA Health Jonsson Comprehensive Cancer CenterHepatocellular CarcinomaInsights
    Looking Ahead in SCLC: ADCs and Other Novel Agents
    Expert Perspectives on Tarlatamab in ES-SCLC
    FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
    x